keyword
MENU ▼
Read by QxMD icon Read
search

Plerixafor

keyword
https://www.readbyqxmd.com/read/28530669/addition-of-plerixafor-to-g-csf-is-useful-to-achieve-efficient-collection-even-in-very-poor-mobilizers-hope-for-patients-with-diminished-hematopoietic-function
#1
M Mohty, P Drillat, J-M Grouin, F Bijou, N Milpied, C Chabannon
No abstract text is available yet for this article.
May 22, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28527129/efficacy-and-safety-of-plerixafor-for-the-mobilization-collection-of-peripheral-hematopoietic-stem-cells-for-autologous-transplantation-in-japanese-patients-with-multiple-myeloma
#2
Masaki Ri, Kosei Matsue, Kazutaka Sunami, Chihiro Shimazaki, Akio Hayashi, Yoshinori Sunaga, Toru Sasaki, Kenshi Suzuki
To evaluate the efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells (HSCs) for autologous transplantation in Japanese patients with multiple myeloma (MM). In a randomized study, patients received G-CSF (filgrastim, 400 µg/m(2)/day) for 4 days prior to the first dose of plerixafor. Starting on Day 4 evening and for up to 4 days, patients received either plerixafor (240 µg/kg/day) + G-CSF group (PG group) or G-CSF alone (G group). Daily apheresis started on Day 5 for up to 4 days, or until ≥6 × 10(6) CD34+ cells/kg were collected...
May 19, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28496091/mobilization-of-hematopoietic-stem-cells-for-hematopoietic-cells-autologous-transplantation-with-use-of-plerixafor
#3
Krzysztof Gawroński, Piotr Rzepecki, Waldemar Sawicki, Jarosław Wajs
BACKGROUND To increase the number of circulating hematopoietic stem cells (HSC) in the blood, mobilization treatments are currently being used. G-CSF and G-CSF plus chemotherapy are the most common methods of hematopoietic stem cells separation used in Poland. MATERIAL AND METHODS We observed patients who failed an effective hematopoietic stem cell mobilization with G-CSF or with G-CSF plus chemotherapy. The separation was considered unsuccessful if within a period of 4 consecutive days of separation, the number of obtained CD 34+ cells was lower than 2...
May 12, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28495640/sources-of-hematopoietic-stem-and-progenitor-cells-and-methods-to-optimize-yields-for-clinical-cell-therapy
#4
REVIEW
Sandhya R Panch, James Szymanski, Bipin N Savani, David F Stroncek
Bone marrow (BM) aspirates, mobilized peripheral blood (PB) and umbilical cord blood (UCB) have developed as graft sources of hematopoietic stem and progenitor cells (HSPC) for stem cell transplantation and other cellular therapeutics. Individualized techniques are necessary to enhance graft HSPC yields and cell quality from each graft source. BM aspirates yield adequate CD34+cells but can result in relative delays in engraftment. Granulocyte-colony stimulating factor (G-CSF) primed bone marrow HSPC may facilitate faster engraftment while minimizing graft-versus-host disease (GVHD) in certain patient subsets...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28485045/performance-and-safety-of-femoral-central-venous-catheters-in-pediatric-autologous-peripheral-blood-stem-cell-collection
#5
Laura Cooling, Sandra Hoffmann, Dawn Webb, Chisa Yamada, Robertson Davenport, Sung Won Choi
INTRODUCTION: Autologous peripheral blood hematopoietic progenitor cell collection (A-HPCC) in children typically requires placement of a central venous catheter (CVC) for venous access. There is scant published data regarding the performance and safety of femoral CVCs in pediatric A-HPCC. METHODS: Seven-year, retrospective study of A-HPCC in pediatric patients collected between 2009 and January 2017. Inclusion criteria were an age ≤ 21 years and A-HPCC using a femoral CVC for venous access...
May 9, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28476490/phase-i-ii-study-of-intravenous-plerixafor-added-to-a-mobilization-regimen-of-g-csf-in-lymphoma-patients-undergoing-autologous-stem-cell-collection
#6
Amanda Cashen, Michael Rettig, Feng Gao, Angela Smith, Camille Abboud, Keith Stockerl-Goldstein, Ravi Vij, Geoffrey Uy, Peter Westervelt, John DiPersio
Plerixafor, given subcutaneously with G-CSF, improves autologous stem cell collection in patients with lymphoma and multiple myeloma. Intravenous (IV) administration of plerixafor allows administration of plerixafor the same day as pheresis, and it may improve stem cell collection. The primary objectives of this Phase I/II study were to determine the maximum tolerated dose of IV plerixafor, and the efficacy of IV plerixafor + G-CSF to mobilize ≥ 2 x 10(6) CD34+ cells/kg from patients with lymphoma. In Phase I, 25 patients were treated with G-CSF + IV plerixafor at escalating doses; in Phase II, 36 patients were treated with G-CSF + plerixafor 0...
May 2, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28455878/impact-of-plerixafor-mozobil-on-hospital-efficiency-a-single-center-experience
#7
Nabih Azar, Maya Ouzegdouh, Sylvain Choquet, Véronique Leblond
Plerixafor (Mozobil) in combination with granulocyte colony-stimulating factor (G-CSF) has shown to increase mobilization of peripheral blood stem cells (PBSC) as compared to G-CSF alone in patients undergoing autologous stem cell transplantation (ASCT). However, up to 25% of patients treated with G-CSF alone still fail mobilization. Adding plerixafor to poor mobilizers allows to rescue these patients from mobilization failure and to reduce the number of apheresis sessions. The goal of this retrospective study was to capture the impact of plerixafor on treatment outcome and on apheresis department efficiency...
April 28, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28434928/hypercvad-chemotherapy-in-mantle-cell-lymphoma-patients-is-associated-with-higher-rates-of-hematopoietic-progenitor-cell-mobilization-failure-despite-plerixafor-rescue
#8
Amandeep Salhotra, Yuan Shan, Ni-Chun Tsai, James F Sanchez, Ibrahim Aldoss, Haris Ali, Tanya Paris, Ricardo Spielberger, Thai M Cao, Auayporn Nademanee, Stephen J Forman, Robert Chen
Induction regimens for mantle cell lymphoma (MCL) can be categorized into highly intensive ones containing cytarabine and less intense regimens such as R (rituximab) CHOP or R-bendamustine. Prior publications have shown R-hyperCVAD can be associated with stem cell mobilization failures. However, those studies did not include the use of plerixafor as rescue for stem cell mobilization failure. We examined our database of 181 consecutive MCL patients from 2005 to 2015 who received upfront therapy with either R-hyperCVAD or less intense chemotherapy (R-bendamustine and R-CHOP only) regimens to assess impact of frontline chemotherapy on collection of hematopoietic cell progenitors prior to autologous stem cell transplant (ASCT)...
April 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28411174/evaluation-of-hematopoietic-stem-cell-mobilization-rates-with-early-plerixafor-administration-time-for-adult-stem-cell-transplantation
#9
Jessica T Stover, J Ryan Shaw, Maragatha Kuchibhatla, Mitchell E Horwitz, Ashley M Engemann
The addition of plerixafor to high-dose colony stimulating growth factor has been shown to improve stem cell mobilization rates in autologous transplant patients with multiple myeloma and non-Hodgkin's lymphoma. This study evaluates the change in administration time of plerixafor to determine if cell mobilization rates are similar between the FDA approved administration time of 11 hours prior to apheresis and an earlier administration time of 16 hours prior to apheresis. Medical records of patient ≥ 18 years of age undergoing autologous stem cell transplantation requiring the use of plerixafor after at least four days of G-CSF therapy to complete stem cell mobilization from 1 January 2010 through 30 September 2014 were retrospectively reviewed...
April 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28409853/a-phase-1-study-of-the-cxcr4-antagonist-plerixafor-in-combination-with-high-dose-cytarabine-and-etoposide-in-children-with-relapsed-or-refractory-acute-leukemias-or-myelodysplastic-syndrome-a-pediatric-oncology-experimental-therapeutics-investigators-consortium
#10
Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, Lie Li, Amina Ahmed, Tanya Trippett, Lia Gore, Margaret E Macy, Aru Narendran, Keith August, Michael J Absalon, Jessica Boklan, Jessica Pollard, Daniel Magoon, Patrick A Brown
BACKGROUND: Plerixafor, a reversible CXCR4 antagonist, inhibits interactions between leukemic blasts and the bone marrow stromal microenvironment and may enhance chemosensitivity. A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose. PROCEDURE: Plerixafor was administered daily for 5 days at four dose levels (6, 9, 12, and 15 mg/m(2) /dose) followed 4 hr later by high-dose cytarabine (every 12 hr) and etoposide (daily)...
April 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28370401/cyclophosphamide-based-stem-cell-mobilization-in-relapsed-multiple-myeloma-patients-a-subgroup-analysis-from-the-phase-iii-trial-relapse
#11
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, Julia Krzykalla, Natalia Becker, Katja Weisel, Richard Noppeney, Hans Martin, Hans W Lindemann, Mathias Haenel, Axel Nogai, Christof Scheid, Hans Salwender, Roland Fenk, Ullrich Graeven, Peter Reimer, Martin Schmidt-Hieber, Martin Goerner, Ingo G H Schmidt-Wolf, Stefan Klein, Anthony D Ho, Hartmut Goldschmidt, Patrick Wuchter
OBJECTIVE: Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM). METHODS: Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG). RESULTS: Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients...
March 31, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28337172/bone-marrow-derived-cell-accumulation-in-the-spinal-cord-is-independent-of-peripheral-mobilization-in-a-mouse-model-of-amyotrophic-lateral-sclerosis
#12
Kyle Peake, John Manning, Coral-Ann Lewis, Kevin Tran, Fabio Rossi, Charles Krieger
Bone marrow-derived cells (BMDCs) are capable of migrating across the blood-brain barrier (BBB) and accumulating in the central nervous system (CNS) when transplanted into recipients conditioned with whole-body irradiation or chemotherapy. We used the chemotherapeutic agents busulfan and treosulfan to condition recipient mice for transplantation with bone marrow (BM) cells isolated from donor mice ubiquitously expressing green fluorescent protein. We attempted to increase the accumulation of BMDCs in the CNS by mobilization of BMDCs using either, or both, granulocyte colony-stimulating factor (GCSF) or plerixafor (AMD3100)...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28323004/fresh-or-cryopreserved-cd34-selected-mobilized-peripheral-blood-stem-and-progenitor-cells-for-the-treatment-of-poor-graft-function-after-allogeneic-hematopoietic-cell-transplantation
#13
Armin Ghobadi, Mark A Fiala, Giridharan Ramsingh, Feng Gao, Camille N Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, Brenda J Grossman, Peter Westervelt, John F DiPersio
CD34(+)-selected stem cell boost (SCB) without conditioning has recently been utilized for poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation with promising results. Unfortunately, many patients have been unable to receive the boost infusion as their donors were unwilling or unable to undergo an additional stem cell collection. Therefore, we conducted this study utilizing either fresh or cryopreserved peripheral blood stem cell products to create CD34(+)-selected boost infusions for the treatment of PGF...
March 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28303154/mesenchymal-stem-cell-administration-in-patients-with-chronic-obstructive-pulmonary-disease-state-of-the-science
#14
REVIEW
Shih-Lung Cheng, Ching-Hsiung Lin, Chao-Ling Yao
Patients with chronic obstructive pulmonary disease (COPD) have chronic, irreversible airway inflammation; currently, there is no effective or curative treatment and the main goals of COPD management are to mitigate symptoms and improve patients' quality of life. Stem cell based therapy offers a promising therapeutic approach that has shown potential in diverse degenerative lung diseases. Preclinical studies have demonstrated encouraging outcomes of mesenchymal stem/stromal cells (MSCs) therapy for lung disorders including emphysema, bronchopulmonary dysplasia, fibrosis, and acute respiratory distress syndrome...
2017: Stem Cells International
https://www.readbyqxmd.com/read/28292947/mobilization-of-allogeneic-peripheral-blood-stem-cell-donors-with-intravenous-plerixafor-mobilizes-a-unique-graft
#15
Mark A Schroeder, Michael P Rettig, Sandra Lopez, Stephanie Christ, Mark Fiala, William Eades, Fazia A Mir, Jin Shao, Kyle McFarland, Kathryn Trinkaus, William Shannon, Elena Deych, Jinsheng Yu, Ravi Vij, Keith Stockerl-Goldstein, Amanda F Cashen, Geoffrey L Uy, Camille N Abboud, Peter Westervelt, John F DiPersio
A single subcutaneous (SC) injection of plerixafor results in rapid mobilization of hematopoietic progenitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis. We hypothesized that changing the route of administration of plerixafor from SC to IV may overcome the low stem cell yields and allow collection in 1 day. A phase 1 trial followed by a phase 2 efficacy trial was conducted in allogeneic sibling donors. The optimal dose of IV plerixafor was determined to be 0.32 mg/kg. The primary outcome of reducing the failure to collect ≥2 × 10(6) CD34(+)/kg recipient weight in 1 apheresis collection to ≤10% was not reached...
May 11, 2017: Blood
https://www.readbyqxmd.com/read/28286619/optimizing-stem-cells-mobilization-strategies-to-ameliorate-patient-outcomes-a-review-of-guide-lines-and-recommendations
#16
REVIEW
Saeed Mohammadi, Ashraf Malek Mohammadi, Mohsen Nikbakht, Amir Hossein Norooznezhad, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood progenitor cells performs in different ways among transplantation centers. Forceful mobilization schedules are comprised of growth factor alone, chemotherapy along with growth factor and also, a newly combination of novel agent such as plerixafor with any approach. With the appearance of numerous modifications in stem cell mobilization field over the past decade and advent of novel stem cell mobilization techniques, it seems to be necessary to review recent publications about stem cell mobilization strategies to respond above cited issues...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28282031/a-phase-1-2-study-of-chemosensitization-with-plerixafor-plus-g-csf-in-relapsed-or-refractory-acute-myeloid-leukemia
#17
G L Uy, M P Rettig, R M Stone, M Y Konopleva, M Andreeff, K McFarland, W Shannon, T R Fletcher, T Reineck, W Eades, K Stockerl-Goldstein, C N Abboud, M A Jacoby, P Westervelt, J F DiPersio
No abstract text is available yet for this article.
March 10, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28274958/cabozantinib-eradicates-advanced-murine-prostate-cancer-by-activating-anti-tumor-innate-immunity
#18
Akash Patnaik, Kenneth D Swanson, Eva Csizmadia, Aniruddh Solanki, Natalie Landon-Brace, Marina P Gehring, Katja Helenius, Brian M Olson, Athalia R Pyzer, Lily C Wang, Olivier Elemento, Jesse Novak, Thomas B Thornley, John M Asara, Laleh Montaser, Joshua J Timmons, Todd M Morgan, Yugang Wang, Elena Levantini, John G Clohessy, Kathleen Kelly, Pier Paolo Pandolfi, Jacalyn M Rosenblatt, David E Avigan, Huihui Ye, Jeffrey M Karp, Sabina Signoretti, Steven P Balk, Lewis C Cantley
Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial patients across several malignancies. Here we show that cabozantinib rapidly eradicates invasive, poorly-differentiated PTEN/p53 deficient murine prostate cancer. This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor...
March 8, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28067870/a-single-center-s-experience-using-four-different-front-line-mobilization-strategies-in-lymphoma-patients-planned-to-undergo-autologous-hematopoietic-cell-transplantation
#19
B M Haverkos, Y Huang, P Elder, L O'Donnell, D Scholl, B Whittaker, S Vasu, S Penza, L A Andritsos, S M Devine, S M Jaglowski
In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line strategy. We report a single institutional experience mobilizing HSCs using four different approaches in lymphoma patients. We prospectively collected mobilization outcomes on patients planned to undergo auto-HCT at Ohio State University...
April 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28040478/cathepsin-k-cleavage-of-sdf-1%C3%AE-inhibits-its-chemotactic-activity-towards-glioblastoma-stem-like-cells
#20
Vashendriya V V Hira, Urška Verbovšek, Barbara Breznik, Matic Srdič, Marko Novinec, Hala Kakar, Jill Wormer, Britt Van der Swaan, Brigita Lenarčič, Luiz Juliano, Shwetal Mehta, Cornelis J F Van Noorden, Tamara T Lah
Glioblastoma (GBM) is the most aggressive primary brain tumor with poor patient survival that is at least partly caused by malignant and therapy-resistant glioma stem-like cells (GSLCs) that are protected in GSLC niches. Previously, we have shown that the chemo-attractant stromal-derived factor-1α (SDF-1α), its C-X-C receptor type 4 (CXCR4) and the cysteine protease cathepsin K (CatK) are localized in GSLC niches in glioblastoma. Here, we investigated whether SDF-1α is a niche factor that through its interactions with CXCR4 and/or its second receptor CXCR7 on GSLCs facilitates their homing to niches...
December 28, 2016: Biochimica et Biophysica Acta
keyword
keyword
44247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"